Contact
Please use this form to send email to PR contact of this press release:
Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
TO:
Please use this form to send email to PR contact of this press release:
Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
TO: